Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

Stock Information for Celcuity Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Celcuity Inc.

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
Celcuity to Participate in Cowen's 44th Annual Health Care Conference
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.